Arch Therapeutics Stock Performance
| ARTH Stock | USD 0.21 0.01 5.00% |
On a scale of 0 to 100, Arch Therapeutics holds a performance score of 1. The firm shows a Beta (market volatility) of 0.68, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Arch Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Arch Therapeutics is expected to be smaller as well. Please check Arch Therapeutics' coefficient of variation, semi variance, relative strength index, as well as the relationship between the treynor ratio and rate of daily change , to make a quick decision on whether Arch Therapeutics' price patterns will revert.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Arch Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Arch Therapeutics demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.3 M |
Arch |
Arch Therapeutics Relative Risk vs. Return Landscape
If you would invest 56.00 in Arch Therapeutics on September 1, 2024 and sell it today you would lose (35.00) from holding Arch Therapeutics or give up 62.5% of portfolio value over 90 days. Arch Therapeutics is currently generating 0.243% in daily expected returns and assumes 18.7209% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Arch, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Arch Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arch Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Arch Therapeutics, and traders can use it to determine the average amount a Arch Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.013
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ARTH | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 18.72 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.24 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average Arch Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arch Therapeutics by adding it to a well-diversified portfolio.
Arch Therapeutics Fundamentals Growth
Arch OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Arch Therapeutics, and Arch Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arch OTC Stock performance.
| Return On Equity | -40.15 | |||
| Return On Asset | -1.14 | |||
| Operating Margin | (364.73) % | |||
| Current Valuation | 12.54 M | |||
| Shares Outstanding | 249.94 M | |||
| Price To Earning | (16.36) X | |||
| Price To Book | 34.61 X | |||
| Price To Sales | 638.65 X | |||
| Revenue | 15.65 K | |||
| EBITDA | (4.71 M) | |||
| Cash And Equivalents | 55 K | |||
| Total Debt | 2.81 M | |||
| Debt To Equity | 2.62 % | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (4.46 M) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 2.6 M | |||
| Retained Earnings | (35.9 M) | |||
| Current Asset | 18.02 K | |||
| Current Liabilities | 3.06 K | |||
About Arch Therapeutics Performance
By evaluating Arch Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Arch Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Arch Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Arch Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company was founded in 2006 and is based in Framingham, Massachusetts. Arch Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.Things to note about Arch Therapeutics performance evaluation
Checking the ongoing alerts about Arch Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Arch Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arch Therapeutics had very high historical volatility over the last 90 days | |
| Arch Therapeutics has some characteristics of a very speculative penny stock | |
| Arch Therapeutics currently holds 2.81 M in liabilities with Debt to Equity (D/E) ratio of 2.62, implying the company greatly relies on financing operations through barrowing. Arch Therapeutics has a current ratio of 0.8, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Arch Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Arch Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arch Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arch to invest in growth at high rates of return. When we think about Arch Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 15.65 K. Net Loss for the year was (5.28 M) with loss before overhead, payroll, taxes, and interest of (35.84 K). | |
| Arch Therapeutics currently holds about 55 K in cash with (4.46 M) of positive cash flow from operations. | |
| Roughly 15.0% of Arch Therapeutics shares are held by company insiders |
- Analyzing Arch Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arch Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Arch Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arch Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arch Therapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Arch Therapeutics' otc stock. These opinions can provide insight into Arch Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Arch OTC Stock analysis
When running Arch Therapeutics' price analysis, check to measure Arch Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Therapeutics is operating at the current time. Most of Arch Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arch Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Therapeutics' price. Additionally, you may evaluate how the addition of Arch Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |